IFNG and myeloid sarcoma: In our study confirming the inadequate IFN-γ secretion of NK cells, IFN-γ levels of CD56bright cells were also indicated to be down-regulated in treated RR-MS patients as well as untreated patients, even after the addition of IL-12; the main stimulator of IFN-γ (127).